COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2

Autor: Szubert, AJ, Pollock, KM, Cheeseman, HM, Alagaratnam, J, Bern, H, Bird, O, Boffito, M, Byrne, R, Cole, T, Cosgrove, CA, Faust, SN, Fidler, S, Galiza, E, Hassanin, H, Kalyan, M, Libri, V, McFarlane, LR, Milinkovic, A, O'Hara, J, Owen, DR, Owens, D, Pacurar, M, Rampling, T, Skene, S, Winston, A, Woolley, J, Yim, YTN, Dunn, DT, McCormack, S, Shattock, RJ, COVAC 1 Study Team

Publikováno v: eClinicalMedicine. 56:101823

Background: lipid nanoparticle (LNP) encapsulated self-amplifying RNA (saRNA) is well tolerated and immunogenic in SARS-CoV-2 seronegative and seropositive individuals aged 18–75. Methods: a phase 2a expanded safety and immunogenicity study of a sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2fb1607ff605f0320f0c4d76cba21074
https://doi.org/10.1016/j.eclinm.2022.101823

Expression Profile of Human Fc Receptors in Mucosal Tissue: Implications for Antibody-Dependent Cellular Effector Functions Targeting HIV-1 Transmission

Autor: Cheeseman, HM, Carias, AM, Evans, AB, Olejniczak, NJ, Ziprin, P, King, DF, Hope, TJ, Shattock, RJ

Publikováno v: PLoS ONE, Vol 11, Iss 5, p e0154656 (2016)

The majority of new Human Immunodeficiency Virus (HIV)-1 infections are acquired via sexual transmission at mucosal surfaces. Partial efficacy (31.2%) of the Thai RV144 HIV-1 vaccine trial has been correlated with Antibody-dependent Cellular Cytotoxi

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=dedup_wf_001::c171ea035f513d13e97226100c1e2626
http://europepmc.org/articles/PMC4862624?pdf=render

Human antibody signatures towards the Chlamydia trachomatis major outer membrane protein after natural infection and vaccination.

Autor: Rosenkrands I; Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark. Electronic address: idr@ssi.dk., Olsen AW; Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark., Knudsen S; Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark., Dehari N; Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark., Juel HB; Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark., Cheeseman HM; Department of Infectious Disease, Imperial College London, London, United Kingdom., Andersen P; Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark; Novo Nordisk Fonden, Hellerup, Denmark., Shattock RJ; Department of Infectious Disease, Imperial College London, London, United Kingdom., Follmann F; Center for Vaccine Research, Department of Infectious Disease Immunology, Statens Serum Institut, Copenhagen, Denmark.

Publikováno v: EBioMedicine [EBioMedicine] 2024 Jun; Vol. 104, pp. 105140. Date of Electronic Publication: 2024 May 13.

Comparison of blood and lymph node cells after intramuscular injection with HIV envelope immunogens.

Autor: Day S; Department of Infectious Disease, Imperial College London, London, United Kingdom., Kaur C; Department of Infectious Disease, Imperial College London, London, United Kingdom., Cheeseman HM; Department of Infectious Disease, Imperial College London, London, United Kingdom., de Groot E; Department of Infectious Disease, Imperial College London, London, United Kingdom.; National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom., McFarlane LR; Department of Infectious Disease, Imperial College London, London, United Kingdom., Tanaka M; National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom., Coelho S; National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom., Cole T; National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom., Lemm NM; Department of Infectious Disease, Imperial College London, London, United Kingdom.; National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom., Lim A; Department of Breast Radiology, Charing Cross Hospital, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom., Sanders RW; Medical Microbiology and Infection Prevention, Amsterdam University Medical Centers (UMC), University of Amsterdam, Amsterdam, Netherlands.; Infectious Diseases, Amsterdam Institute for Infection and Immunity, Amsterdam, Netherlands.; Dept Microbiology and Immunology, Weill Cornell Medical Center, Cornell University, New York, NY, United States., Asquith B; Department of Infectious Disease, Imperial College London, London, United Kingdom., Shattock RJ; Department of Infectious Disease, Imperial College London, London, United Kingdom., Pollock KM; Department of Infectious Disease, Imperial College London, London, United Kingdom.; National Institute for Health and Care Research (NIHR) Imperial Clinical Research Facility, Imperial College Healthcare National Health Service (NHS) Trust, London, United Kingdom.

Publikováno v: Frontiers in immunology [Front Immunol] 2022 Oct 05; Vol. 13, pp. 991509. Date of Electronic Publication: 2022 Oct 05 (Print Publication: 2022).

Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trial.

Autor: Pollock KM; Department of Infectious Disease, Imperial College London.; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Cheeseman HM; Department of Infectious Disease, Imperial College London., Szubert AJ; MRC Clinical Trials Unit at UCL, London, UK., Libri V; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, London, UK., Boffito M; Department of Infectious Disease, Imperial College London.; Chelsea & Westminster Hospital, London., Owen D; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Bern H; MRC Clinical Trials Unit at UCL, London, UK., O'Hara J; Department of Infectious Disease, Imperial College London., McFarlane LR; Department of Infectious Disease, Imperial College London., Lemm NM; Department of Infectious Disease, Imperial College London., McKay PF; Department of Infectious Disease, Imperial College London., Rampling T; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, London, UK., Yim YTN; NIHR UCLH Clinical Research Facility and NIHR UCLH Biomedical Research Centre, London, UK., Milinkovic A; Chelsea & Westminster Hospital, London., Kingsley C; Department of Infectious Disease, Imperial College London., Cole T; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Fagerbrink S; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Aban M; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Tanaka M; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Mehdipour S; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Robbins A; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Budd W; NIHR Imperial Clinical Research Facility and NIHR Imperial Biomedical Research Centre, London, UK., Faust SN; NIHR Southampton Clinical Research Facility and Biomedical Research Centre, University Hospital Southampton NHS Foundation Trust, Southampton, UK; Faculty of Medicine and Institute for Life Sciences, University of Southampton, Southampton, UK., Hassanin H; Surrey Clinical Research Facility, Faculty of Health and Medical Sciences, University of Surrey, Guildford, UK., Cosgrove CA; Centre for Infection, St George's, University of London, London, United Kingdom., Winston A; Department of Infectious Disease, Imperial College London., Fidler S; Department of Infectious Disease, Imperial College London., Dunn DT; MRC Clinical Trials Unit at UCL, London, UK., McCormack S; MRC Clinical Trials Unit at UCL, London, UK., Shattock RJ; Department of Infectious Disease, Imperial College London.

Publikováno v: EClinicalMedicine [EClinicalMedicine] 2022 Feb; Vol. 44, pp. 101262. Date of Electronic Publication: 2022 Jan 14.